24/7 Market News Snapshot 27 Jun 2024 – NLS Pharmaceutics Ltd. Ordinary Shares (NASDAQ: NLSP)

June 27, 2024 7:22

Press Release

DENVER, Colo., 27 June, 2024 (247marketnews.com) – (Nasdaq:NLSP) are discussed in this article.
NLS Pharmaceutics Ltd. experiences a surge in its stock price, reaching $0.374 in the pre-market session, reflecting a remarkable 105.37% increase from the previous day’s close of $0.183. The trading volume of 20.5 million shares indicates significant investor interest, hinting at a bullish trend for the company. This spike presents an enticing opportunity for investors seeking to capitalize on the upward momentum of NLS Pharmaceutics Ltd.

In a significant development, NLS Pharmaceutics Ltd., a leading Swiss clinical-stage biopharmaceutical company specializing in central nervous system disorders, has unveiled groundbreaking preclinical findings in the treatment of Parkinson’s Disease (PD). The research focused on alpha-synuclein (α-synuclein) and the A53T mutation, showcasing the compounds’ potential to revolutionize PD treatment by enhancing neurite outgrowth, a crucial indicator of neuronal health and regeneration.

CEO Alex Zwyer expressed optimism about the results, which demonstrate the compounds’ promise in modulating neuronal health and α-synuclein dynamics. Based on the success of AEX-23, NLS plans to develop new chemical successors like AEX-230 and AEX-231, targeting cathepsins associated with neurodegenerative disorders. The company’s collaborations with global partners and leading scientists underscore its commitment to advancing innovative therapies for complex CNS disorders.

NLS Pharmaceutics Ltd. aims to leverage these groundbreaking discoveries to redefine the treatment landscape for neurodegenerative disorders. As the company progresses with in vitro and in vivo studies, it remains dedicated to pioneering transformative therapies to address unmet medical needs in the field. Interested parties can access further information on NLS’ advancements and initiatives by visiting www.nlspharma.com.

For detailed disclosures and forward-looking statements regarding NLS Pharmaceutics Ltd., investors are advised to review the company’s filings with the Securities and Exchange Commission. To stay informed on NLS’ developments, visit their official website or contact Investor Relations via InvestorRelations@nls-pharma.com.

Source: NLS Pharmaceutics AG. For the complete press release, kindly refer to accesswire.com.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 Market News, Inc Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.